and there's the rub ....
Analysts from Cantor Fitzgerald believed Mesoblast had sufficient data to allay the FDA’s concerns.
“MESO has potency assays and experience from clinical trials to correlate this potency to measurable clinical outcomes,” the analysts said in a note to investors.
“We think MESO will be able to address the concerns that were raised in the briefing materials. The topics of discussion were already anticipated by the company, and MESO has been preparing for the AdCom (advisory committee).”
Tip: 3.84 close
MSB Trading - Aug 2020 on, page-924
-
- There are more pages in this discussion • 1,461 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
0.003(0.21%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.20 | $1.15 | $2.026M | 1.730M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 34436 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 26120 | 7 |
View Market Depth
| Last trade - 12.36pm 16/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |